Aspire Biopharma

ASBP

Market cap $12.6M

ESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provides a business update for the quarter ended September 30, 2025. Q3 2025 and Recent Highlights Expanded its scientific team with the addition of Mark J.

ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, is pleased to announce that on November 3, 2025, it submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company's lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval.

ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, has expanded its scientific team with the November 4, 2025 addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida.

ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced its successful participation in the CPHI Frankfurt trade show, the world's largest pharmaceutical event. The Company engaged in numerous strategic discussions with global pharmaceutical companies regarding technical collaboration and licensing opportunities for its lead product candidate, a novel sublingual high-dose aspirin.

ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the filing of an omnibus patent application with the U.S. Patent and Trademark Office for its sublingual delivery technology. This application - which seeks patent protection of Aspire's proprietary technology in a variety of classes of drugs and other substances--focuses exclusively on protecting the Company's advanced sublingual drug delivery system, which is designed to enhance the pharmacokinetic performance of Active Pharmaceutical Ingredients ("APIs") and other substances into the bloodstream, increasing bioavailability and improving speed of onset.

Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and a More-Rapid ED Medication Presentation and 1x1 Investor Meetings Scheduled Across the Two-Day Virtual Conference ESTERO, FLORIDA / ACCESS Newswire / October 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending sublingual drug delivery technology, today announced that Kraig Higginson, Interim CEO of Aspire Biopharma will be presenting and participating in 1x1 meetings at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The presentation will feature updates on the company's pipeline progress and key milestones expected throughout the remainder of 2025 and early 2026.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 0.2% on Thursday.

Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate Commercialization Future Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL / ACCESS Newswire / October 1, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending sublingual drug delivery technology, today announced pipeline progress and key milestones expected through the remainder of 2025 and early 2026. The company is focusing its pipeline on reformulating approved drugs for multi-billion-dollar markets by utilizing its disruptive, patent-pending sublingual delivery technology.

BUZZ BOMB™ engages three specialized fitness influencers to grow the brand https://www.instagram.com/bobbymaximus/ https://www.instagram.com/midwest_kong/ https://www.instagram.com/ifbbpro_moose_the_stallion/ The influencers have hundreds of thousands of followers across social platforms BUZZ BOMB's™ influencers known for their authenticity and ability to create genuine connections with their followers in the fitness and health world Sublingual delivery of 50mg of caffeine to the user in less than two minutes BUZZ BOMB™ is available for purchase at buzzbomb.buzz , the Company's E-commerce website ESTERO, FL / ACCESS Newswire / September 17, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced it has launched its influencer marketing campaign designed to drive conversion, brand awareness and loyalty for its innovative BUZZ BOMB™ pre-workout product. Featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), BUZZ BOMB™ provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed for immediate effect.

Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity SupraNaturals is a leading private label manufacturer in the health and wellness industry BUZZ BOMB™ pre-workout: 50mg caffeine for energy and focus. Boosts performance potential.